Introduction
Y ersiniosis, a foodborne disease, is characterized by symptoms including diarrhea, fever, abdominal pain, and vomiting (Drummond et al., 2012) . Fluoroquinolones (FQ) are used for the treatment of this infection, particularly in immunocompromised individuals (Capilla et al., 2004) . In Gram-negative bacteria, three mechanisms of FQ resistance have been described including target gene mutation(s); reduction in drug accumulation; and plasmid-mediated quinolone resistance (PMQR). DNA gyrase and DNA topoisomerase IV are tetrameric enzymes and are the targets for quinolone drugs. Resistance has been attributed to chromosomal mutations in the corresponding subunit-encoding genes (gyrA, gyrB for DNA gyrase and/or parC and parE for topoisomerase IV) (Ruiz, 2003) . Within these loci, the quinoloneresistance-determining region (QRDR) is a mutational hot spot (Fà brega et al., 2010) . Several mutations have already been identified in gyrA in Yersinia enterocolitica, the most common of which lead to amino acid substitutions at Ser-83 and Asp-87, conferring resistance to nalidixic acid (Sánchez-Céspedes et al., 2003; Capilla et al, 2004; Sihvonen et al., 2011) .
Compared to other members of the Enterobacteriaceae, quinolone resistance in Y. enterocolitica is not commonly encountered. In this study, chromosomal-and plasmidmediated resistance mechanisms were investigated in three nalidixic acid-resistant Y. enterocolitica recovered from humans in Switzerland. The data presented extend our understanding of this resistance type in these foodborne pathogens.
Materials and Methods

Bacterial strains and culture conditions
Three Y. enterocolitica strains (Table 1) , isolated between 2006 and 2010 from humans in Switzerland, along with Y. enterocolitica 8081 and a reference-strain Y. enterocolitica ATCCÔ9610, were included in this study. All bacteria were subcultured and maintained as described previously (Murphy et al., 2010) .
Antimicrobial susceptibility testing
Susceptibility testing was performed by disc diffusion, using a panel of antimicrobial agents including the following: amoxicillin-clavulanic acid 30 (10 + 20) lg, ampicillin 10 lg, cefoxitin 30 lg, ceftazidime 30 lg, cefpodoxime 10 lg, cefuroxime 30 lg, cephalothin 30 lg, ciprofloxacin 5 lg, gentamicin 10 lg, kanamycin 30 lg, nalidixic acid 30 lg, streptomycin 10 lg, tetracycline 30 lg, and trimethoprim/sulfamethoxazole 25 (1.25 + 23.75) lg.
Susceptibility or resistance was interpreted according to the Clinical and Laboratory Standards Institute (CLSI, 2008) guidelines and minimum inhibitory concentrations (MIC) for nalidixic acid and ciprofloxacin were determined by E-test on Mueller-Hinton agar following the manufacturer's instructions (AB-Biodisk, Solna, Sweden). E-tests were also performed in the presence of the efflux pump inhibitor phenylalaninearginine-b-naphthylamide, which was added to MuellerHinton agar plates at a concentration of 20 mg/L. Escherichia coli ATCCÔ25922 was used for quality-control purposes.
Detection of virulence markers and the Y. enterocolitica-specific 16S rRNA gene by polymerase chain reaction (PCR)
Template DNA was prepared and three specific primer sets (Eurofins MWG Operon, Ebersberg, Germany) were used to amplify ail (Falcã o et al., 2004) , pYad (Lantz et al., 1998) , and the Y. enterocolitica-specific chromosomal 16S rRNA genes (Murphy et al., 2010) . Amplification reactions were performed as described previously (Murphy et al., 2010) .
PCR amplification and DNA sequence analysis of QRDR and PMQR QRDR containing regions of the target genes were amplified by PCR. Primer sequences and PCR conditions applied in 50-lL final reaction mixtures are shown in Supplementary Table S1 (Supplementary Data are available online at www.liebertpub .com/fpd). DNA sequences were analyzed for mutations using DNAStar software (Madison, WI), BLAST (http:// blast.ncbi.nlm.nih.gov/), and ClustalW (http://www.ebi .ac.uk/clustalw). Similarly, PMQR primers and amplification conditions are shown in Supplementary Table S2. All amplicons produced were separated by electrophoresis in a 1.5% agarose gel (SeaKem Ò LE Agarose, Lonza Wokingham, Ltd., UK) containing 0.1 lg/mL EB (Sigma, Ireland) in 1 X Trisboric acid-EDTA buffer (pH 8) (Sigma).
Results and Discussion
The three Y. enterocolitica strains were isolated from humans between 2006 and 2010, in Switzerland. Two of the isolates were bio/serotypes 4:O3 (506-06 and 10-2307) and are classified as pathogenic. The remaining isolate was of biotype 1A (871-07). Isolates 506-06 and 10-2307 harbored the large pVYe plasmid of 67-kb (data not shown) and were positive for the ail and pYad markers, features associated with pathogenic Y. enterocolitica bio/serotypes (Lantz et al., 1998; Falcã o et al., 2004; Thisted Lambertz et al., 2006) . Isolate 871-07 did not contain this plasmid, consistent with the lack of ail and pYad markers, and the 1A biotype.
All three clinical isolates were resistant to nalidixic acid by disk diffusion with resistance profiles including 506-06: AmpKfNaSSxt; 871-07: AmcAmpKfNa; 10-2307: AmpKfNa. Two of the three clinical isolates (506-06 and 871-7, Table 1 ) were resistant to nalidixic acid with MIC > 256 mg/L. All three clinical isolates were susceptible to ciprofloxacin and none contained PMQR markers (data not shown).
The amino acid substitutions associated with nalidixic acid resistance are summarized in Table 2 . A mutation in gyrA was identified in isolate 871-07 consistent with the substitution of Ser-83-Ile, and an Asp-87-Tyr substitution was identified in isolate 506-06, similar to the change in Y. enterocolitica 8081. Mutations in these loci contributed to a nalidixic acid-resistant phenotype, as determined by E-test (Table 1) . Furthermore, no mutations in gyrB, parC, or parE were detected.
Measurement of MICs to nalidixic acid and ciprofloxacin in the presence of phenylalanine-arginine-b-naphthylamide contributed to an increase in susceptibility with the exception of the reference strain, in respect of ciprofloxacin (Table 1) . These findings suggest that efflux activity in this bacterium contributes to quinolone/FQ resistance, a feature that confirms earlier observations (Capilla et al., 2004) .
Compared to other Enterobacteriaceae, small numbers of Y. enterocolitica resistant to nalidixic acid have been reported to date (Sánchez-Céspedes et al., 2003; Capilla et al., 2004; Fà brega et al., 2010; Sihvonen et al., 2011; Fredriksson-Ahomaa et al., 2012) . Although target gene mutations in gyrA are the primary mechanism of resistance to nalidixic acid, efflux pump activity, also contributes to support this phenotype. This finding supports data reported earlier (Capilla et al., 2004) . Importantly, all three clinical isolates remain susceptible to ciprofloxacin. NALIDIXIC ACID-RESISTANT Y. ENTEROCOLITICA
